Preventing pre-eclampsia: Evaluating AspiRin Low-dose regimens following risk ScreeningA multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomised trial of low-dose aspirin for women at increased risk pre-eclampsia in Ghana, Kenya and South Africa, to prevent pre-eclampsia and improve maternal and newborn outcomes.

Concept Foundation0 个研究点目标入组 20,576 人开始时间: 2024年2月27日最近更新: 2024年4月8日

试验速览

暂无简介。

•Pregnant women at <20 weeks’ gestation, identified as being at high risk of pre-eclampsia, according to the restricted-variable FMF algorithm combining maternal history and MAP
•Women with any live pregnancy (singleton or multiple).
•Women intend to give birth in a participating study facility/care network

•Women identified by FMF screening algorithm as low risk
•Women with a known contraindication to antiplatelet therapy, such as hypersensitivity reaction to any NSAID, or patients with asthma who have a history of aspirin-induced acute bronchospasm
•Multiple pregnancy
•Women with known bleeding disorders (such as von Willebrand’s disease or peptic ulceration)
•Long-term use of nonsteroidal anti-inflammatory medication
•Women who have taken aspirin regularly in the 28 days prior to screening
•A known major fetal anomaly that requires pregnancy termination
•Currently participating in another drug trial
•Unable or unwilling to provide informed consent.

发起方

Concept Foundation